The AIDS Research Consortium of Atlanta filed the civil rights complaint with HHS on Tuesday. The document, filed in conjunction with the Center for Health Law and Policy Innovation of Harvard School of Law, alleged that the insurers set high prices for the HIV drugs to discourage people with expensive chronic conditions — like AIDS — from joining their insurance plans.
“They pick the patients who are less expensive and they leave the more expensive patients to the other companies,” said Melanie Thompson, MD, founder and principal investigator for the AIDS Research Consortium of Atlanta.
Dr. Thompson investigated the companies and found that through their plans, HIV and AIDS patients were paying $550 for treatment, yet only $60 for a rheumatoid arthritis medication just as expensive to produce, according to WSB-TV.
Following Dr. Thompson’s investigation, Alabama, Illinois, Louisiana, Tennessee, Wisconsin and Pennsylvania noticed similar issues and filed discrimination complaints against a handful of insurers, including Highmark and Anthem Blue Cross Blue Shield.
More articles on supply chain:
Is Mylan really the bad guy? 4 thoughts from a leading healthcare strategist on the big picture of pharma price hikes
Weighing the cost of care: How hospitals accommodate obese patients
New York attorney general investigates Mylan over potential antitrust violations in school contracts
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.